We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$85M
Cap. Flow
-$603M
Cap. Flow %
-18.9%
Top 10 Hldgs %
36.68%
Holding
85
New
17
Increased
26
Reduced
11
Closed
10
Avg Time Held
2.9 quarters
Top 10 Avg Time Held
2.6 quarters
Top 20 Avg Time Held
2.4 quarters

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$75.5M
2
SYRE icon
Spyre Therapeutics
SYRE
+$67.4M
3
EXAS icon
Exact Sciences
EXAS
+$62.8M
4
INSP icon
Inspire Medical Systems
INSP
+$52.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$50.1M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$50.9M
2
PCVX icon
Vaxcyte
PCVX
+$27.5M
3
CGEM icon
Cullinan Oncology
CGEM
+$22.7M
4
TRML icon
Tourmaline Bio
TRML
+$20.8M
5
ARGX icon
argenx
ARGX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.98%
2 Miscellaneous 38.71%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.7B
$104M 3.28%
759,009
+28,800
+4% +$3.95M
2023 Q1
5 quarters
CGON icon
2
CG Oncology
CGON
$5.46B
$104M 3.28%
3,309,507
+2,179,272
+193% +$75.5M
2024 Q1
1 quarter
XENE icon
3
Xenon Pharmaceuticals
XENE
$3.26B
$99.8M 3.13%
2,560,573
+1,252,562
+96% +$50.1M
2022 Q4
6 quarters
APGE icon
4
DELISTED
Apogee Therapeutics
APGE
$94.1M 2.95%
2,392,042
+549,527
+30% +$26.7M
2023 Q3
3 quarters
GH icon
5
Guardant Health
GH
$22B
$81.1M 2.54%
2,807,968
+331,164
+13% +$7.71M
2023 Q2
4 quarters
LEGN icon
6
Legend Biotech
LEGN
$3.8B
$74M 2.32%
1,669,720
+425,925
+34% +$19.6M
2022 Q4
6 quarters
ARGX icon
7
argenx
ARGX
$52B
$71.8M 2.25%
166,924
-52,900
-24% -$20.2M
2023 Q4
2 quarters
ALGN icon
8
Align Technology
ALGN
$10.1B
$66.4M 2.08%
275,207
+105,955
+63% +$29.5M
2022 Q4
6 quarters
MRVI icon
9
Maravai LifeSciences
MRVI
$976M
$64.6M 2.03%
9,024,037
+1,802,077
+25% +$15.6M
2023 Q2
4 quarters
PCVX icon
10
Vaxcyte
PCVX
$10.6B
$61M 1.91%
808,303
-404,400
-33% -$27.5M
2022 Q4
6 quarters
SYRE icon
11
Spyre Therapeutics
SYRE
$7.36B
$59.1M 1.85%
2,514,538
+1,999,538
+388% +$67.4M
2023 Q4
2 quarters
GKOS icon
12
Glaukos
GKOS
$9.82B
$58.8M 1.84%
496,576
+45,900
+10% +$4.87M
2022 Q4
6 quarters
VKTX icon
13
Viking Therapeutics
VKTX
$3.28B
$58.7M 1.84%
1,106,905
+393,805
+55% +$25.8M
2024 Q1
1 quarter
IRTC icon
14
iRhythm Holdings
IRTC
$3.47B
$56.7M 1.78%
526,357
+43,100
+9% +$4.4M
2022 Q4
6 quarters
INSP icon
15
Inspire Medical Systems
INSP
$1.98B
$50.8M 1.59%
379,443
+277,951
+274% +$52.6M
2023 Q3
3 quarters
EXAS icon
16
DELISTED
Exact Sciences
EXAS
$48.2M 1.51%
+1,141,678
New +$62.8M
2024 Q2
0 quarters
KROS icon
17
Keros Therapeutics
KROS
$219M
$44.9M 1.41%
982,209
+244,830
+33% +$13.2M
2023 Q2
4 quarters
ISRG icon
18
Intuitive Surgical
ISRG
$147B
$44.7M 1.4%
100,500
– –
2024 Q1
1 quarter
DAWN icon
19
DELISTED
Day One Biopharmaceuticals
DAWN
$41.8M 1.31%
3,035,904
+862,200
+40% +$12.6M
2022 Q4
6 quarters
RGEN icon
20
Repligen
RGEN
$11.4B
$40.8M 1.28%
323,509
+180,673
+126% +$28.3M
2023 Q2
4 quarters
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$40.8M 1.28%
2,898,639
+230,090
+9% +$3.75M
2024 Q1
1 quarter
TMO icon
22
Thermo Fisher Scientific
TMO
$249B
$39M 1.22%
70,449
+23,300
+49% +$13.3M
2023 Q2
4 quarters
KNSA icon
23
Kiniksa Pharmaceuticals
KNSA
$6.14B
$38.4M 1.21%
2,058,303
+665,587
+48% +$12.5M
2024 Q1
1 quarter
PEN icon
24
Penumbra
PEN
$12.6B
$38.3M 1.2%
212,594
-83,298
-28% -$16.6M
2022 Q4
6 quarters
KIDS icon
25
OrthoPediatrics
KIDS
$570M
$31.9M 1%
1,107,770
– –
2022 Q4
6 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2024 Portfolio in Review

As of Q2 2024, Braidwell held 85 positions worth $3.19B, up 2.7% from $3.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $603M in Q2 2024, closing 10 positions and reducing 11 holdings. Its most notable exit was Tourmaline Bio, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Exact Sciences worth $48.2M.

  • Braidwell's largest Q2 2024 buy was Exact Sciences: 1,141,678 shares worth $48.2M.
  • Braidwell added most to CG Oncology in Q2 2024, an estimated $75.5M increase.
  • Braidwell's biggest Q2 2024 reduction was Transmedics, cutting an estimated $50.9M.
  • Braidwell fully exited Tourmaline Bio in Q2 2024, selling an estimated $20.8M.
  • Braidwell's ten largest holdings make up 37% of its $3.19B portfolio in Q2 2024.
  • Braidwell opened 17 new positions and closed 10 in Q2 2024.
  • Braidwell's portfolio value rose 2.7% quarter-over-quarter to $3.19B.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.